<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33029654</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a <sup>18</sup>F-2-fluoro-2-deoxy-D-glucose-positron emission tomography study.</ArticleTitle><Pagination><StartPage>1124</StartPage><EndPage>1133</EndPage><MedlinePgn>1124-1133</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-020-05053-w</ELocationID><Abstract><AbstractText Label="PURPOSE">To assess the brain metabolic correlates of the different regional extent of ALS, evaluated with the King's staging system, using brain <sup>18</sup>F-2-fluoro-2-deoxy-D-glucose-PET (<sup>18</sup>F-FDG-PET).</AbstractText><AbstractText Label="METHODS">Three hundred ninety ALS cases with King's stages 1, 2, and 3 (n&#x2009;=&#x2009;390), i.e., involvement of 1, 2, and 3 body regions respectively, underwent brain <sup>18</sup>F-FDG-PET at diagnosis. King's stage at PET was derived from ALSFRS-R and was regressed out against whole-brain metabolism in the whole sample. The full factorial design confirmed the hypothesis that differences among groups (King's 1, King's 2, King's 3, and 40 healthy controls (HC)) existed overall. Comparisons among stages and between each group and HC were performed. We included age at PET and sex as covariates.</AbstractText><AbstractText Label="RESULTS">Brain metabolism was inversely correlated with stage in medial frontal gyrus bilaterally, and right precentral and postcentral gyri. The full factorial design resulted in a significant main effect of groups. There was no significant difference between stages 1 and 2. Comparing stage 3 to stage 1+2, a significant relative hypometabolism was highlighted in the former in the left precentral and medial frontal gyri, and in the right medial frontal, postcentral, precentral, and middle frontal gyri. The comparisons between each group and HC showed the extension of frontal metabolic changes from stage 1 to stage 3, with the larger metabolic gap between stages 2 and 3.</AbstractText><AbstractText Label="CONCLUSIONS">Our findings support the hypothesis that in ALS, the propagation of neurodegeneration follows a corticofugal, regional ordered pattern, extending from the motor cortex to posterior and anterior regions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5876-4079</Identifier><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Pede</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabras</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardo</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arena</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Positron Emission Tomography Centre AFFIDEA-IRMET S.p.A, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ovidio</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven - University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB, Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pagani</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_UU_00005/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>The Joint Programme - Neurodegenerative Disease Research (Strength and Brain-Mend projects)</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>RF-2016-02362405</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant><Grant><GrantID>259867</GrantID><Agency>Seventh Framework Programme</Agency><Country/></Grant><Grant><GrantID>PRIN 2017SNW5MB</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>INSPIRED Project</GrantID><Agency>Fondation Thierry Latran</Agency><Country/></Grant><Grant><GrantID>Department of Excellence grant</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">18F-FDG-PET</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">King&#x2019;s staging system</Keyword></KeywordList><CoiStatement>Antonio Canosa, Cristina Moglia, Umberto Manera, Rosario Vasta, Francesca Di Pede, Sara Cabras, Davide Nardo, Vincenzo Arena, Maurizio Grassano, Fabrizio D&#x2019;Ovidio, and Marco Pagani report no disclosures. Andrea Calvo has received a research grant from Cytokinetics. Koen Van Laere and Philip Van Damme hold a senior clinical investigatorship of FWO-Vlaanderen. Philip Van Damme is supported by E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, the ALS Liga Belgi&#xeb;, and the KU Leuven funds &#x201c;Een Hart voor ALS,&#x201d; &#x201c;Laeversfonds voor ALS Onderzoek,&#x201d; and the &#x201c;Val&#xe9;ry Perrier Race against ALS Fund.&#x201d; Adriano Chi&#xf2; serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Cytokinetics, and AveXis, and has received a research grant from Italfarmaco.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33029654</ArticleId><ArticleId IdType="mid">EMS97800</ArticleId><ArticleId IdType="pmc">PMC8041703</ArticleId><ArticleId IdType="doi">10.1007/s00259-020-05053-w</ArticleId><ArticleId IdType="pii">10.1007/s00259-020-05053-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry. 2015;86:168&#x2013;173. doi: 10.1136/jnnp-2013-307223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-307223</ArticleId><ArticleId IdType="pubmed">24769471</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet Lond Engl. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain J Neurol. 2012;135:847&#x2013;852. doi: 10.1093/brain/awr351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph Lateral Scler Mot Neuron Disord Off Publ World Fed Neurol Res Group Mot Neuron Dis. 2000;1:293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Front Degener. 2014;15:279&#x2013;284. doi: 10.3109/21678421.2014.897357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.897357</ArticleId><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Caiazzo G, Di Nardo F, Fratello M, Santangelo G, Siciliano M, et al. High angular resolution diffusion imaging abnormalities in the early stages of amyotrophic lateral sclerosis. J Neurol Sci. 2017;380:215&#x2013;222. doi: 10.1016/j.jns.2017.07.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.07.039</ArticleId><ArticleId IdType="pubmed">28870572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino P, Rucco R, Jacini F, Trojsi F, Lardone A, Baselice F, et al. Brain functional networks become more connected as amyotrophic lateral sclerosis progresses: a source level magnetoencephalographic study. NeuroImage Clin. 2018;20:564&#x2013;571. doi: 10.1016/j.nicl.2018.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.08.001</ArticleId><ArticleId IdType="pmc">PMC6120607</ArticleId><ArticleId IdType="pubmed">30186760</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Danielian LE, Braun LE, Wu T. Longitudinal diffusion imaging across the C9orf72 clinical spectrum. J Neurol Neurosurg Psychiatry. 2018;89:53&#x2013;60. doi: 10.1136/jnnp-2017-316799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316799</ArticleId><ArticleId IdType="pmc">PMC6454927</ArticleId><ArticleId IdType="pubmed">29054917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012;69:856&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595157</ArticleId><ArticleId IdType="pubmed">22409939</ArticleId></ArticleIdList></Reference><Reference><Citation>Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, N&#xe5;gren K, et al. EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103&#x2013;2110. doi: 10.1007/s00259-009-1264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-009-1264-0</ArticleId><ArticleId IdType="pubmed">19838705</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12:575&#x2013;593. doi: 10.1007/s12021-014-9235-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-014-9235-4</ArticleId><ArticleId IdType="pubmed">24952892</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Front Degener. 2017;18:153&#x2013;174. doi: 10.1080/21678421.2016.1267768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, Manera U, Vasta R, Brunetti M, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019;93:e984&#x2013;e994. doi: 10.1212/WNL.0000000000008063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008063</ArticleId><ArticleId IdType="pmc">PMC6745732</ArticleId><ArticleId IdType="pubmed">31409738</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, Chi&#xf2; A, Valentini MC, &#xd6;berg J, Nobili F, Calvo A, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Pagani M, Cistaro A, Montuschi A, Iazzolino B, Fania P, et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology. 2016;86:44&#x2013;49. doi: 10.1212/WNL.0000000000002242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002242</ArticleId><ArticleId IdType="pubmed">26590270</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Sideris DI, Carroll E, Rotariu S, Salomonsson S, Tzioras M, et al. Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 2018;135:213&#x2013;226. doi: 10.1007/s00401-017-1797-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1797-4</ArticleId><ArticleId IdType="pmc">PMC5773656</ArticleId><ArticleId IdType="pubmed">29273900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, M&#xfc;ller H-P, Del Tredici K, Brettschneider J, Pinkhardt EH, Lul&#xe9; D, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain J Neurol. 2014;137:1733&#x2013;1740. doi: 10.1093/brain/awu090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu090</ArticleId><ArticleId IdType="pubmed">24736303</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller H-P, Turner MR, Grosskreutz J, Abrahams S, Bede P, Govind V, et al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:570&#x2013;579. doi: 10.1136/jnnp-2015-311952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311952</ArticleId><ArticleId IdType="pubmed">26746186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, M&#xfc;ller H-P, Del Tredici K, Lul&#xe9; D, Gorges M, Braak H, et al. Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J Neurol Neurosurg Psychiatry. 2018;89:374&#x2013;381. doi: 10.1136/jnnp-2017-316365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316365</ArticleId><ArticleId IdType="pmc">PMC5869447</ArticleId><ArticleId IdType="pubmed">29101254</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R, de Reus MA, Scholtens LH, van den Berg LH, van den Heuvel MP. Simulating disease propagation across white matter connectome reveals anatomical substrate for neuropathology staging in amyotrophic lateral sclerosis. NeuroImage. 2016;124:762&#x2013;769. doi: 10.1016/j.neuroimage.2015.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.04.005</ArticleId><ArticleId IdType="pubmed">25869856</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier JM, van der Burgh HK, Nitert AD, Bede P, de Lange SC, Hardiman O, et al. Connectome-based propagation model in amyotrophic lateral sclerosis. Ann Neurol. 2020;87:725&#x2013;738. doi: 10.1002/ana.25706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25706</ArticleId><ArticleId IdType="pmc">PMC7186838</ArticleId><ArticleId IdType="pubmed">32072667</ArticleId></ArticleIdList></Reference><Reference><Citation>van Weehaeghe D, Ceccarini J, Willekens SM, de Vocht J, van Damme P, van Laere K. Is there a glucose metabolic signature of spreading TDP-43 pathology in amyotrophic lateral sclerosis? Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of. 2017;</Citation><ArticleIdList><ArticleId IdType="pubmed">29166751</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86:45&#x2013;49. doi: 10.1136/jnnp-2013-306865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306865</ArticleId><ArticleId IdType="pubmed">24463480</ArticleId></ArticleIdList></Reference><Reference><Citation>Chipika RH, Finegan E, Li Hi Shing S, Hardiman O, Bede P. Tracking a fast-moving disease: longitudinal markers, monitoring, and clinical trial endpoints in ALS. Front Neurol. 2019;10:229. doi: 10.3389/fneur.2019.00229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00229</ArticleId><ArticleId IdType="pmc">PMC6433752</ArticleId><ArticleId IdType="pubmed">30941088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer&#x2019;s disease. Neurology. 1998;50:1585&#x2013;1593. doi: 10.1212/WNL.50.6.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.50.6.1585</ArticleId><ArticleId IdType="pubmed">9633698</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25:1201&#x2013;1217. doi: 10.1111/ene.13728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13728</ArticleId><ArticleId IdType="pubmed">29932266</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2018;45:1546&#x2013;1556. doi: 10.1007/s00259-018-4033-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-4033-0</ArticleId><ArticleId IdType="pubmed">29717332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, Pagani M. Imaging in amyotrophic lateral sclerosis: MRI and PET. Curr Opin Neurol. 2019;32:740&#x2013;746. doi: 10.1097/WCO.0000000000000728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000728</ArticleId><ArticleId IdType="pubmed">31335337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>